ATE502958T1 - Gegen inaktivierung resistenter faktor viii - Google Patents

Gegen inaktivierung resistenter faktor viii

Info

Publication number
ATE502958T1
ATE502958T1 AT06004484T AT06004484T ATE502958T1 AT E502958 T1 ATE502958 T1 AT E502958T1 AT 06004484 T AT06004484 T AT 06004484T AT 06004484 T AT06004484 T AT 06004484T AT E502958 T1 ATE502958 T1 AT E502958T1
Authority
AT
Austria
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Application number
AT06004484T
Other languages
German (de)
English (en)
Inventor
Randal J Kaufman
Steven W Pipe
Kagehiro Amano
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE502958T1 publication Critical patent/ATE502958T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06004484T 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii ATE502958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US1778596P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ATE502958T1 true ATE502958T1 (de) 2011-04-15

Family

ID=26688196

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06004484T ATE502958T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii
AT97927596T ATE319817T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97927596T ATE319817T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Country Status (10)

Country Link
US (2) US6838437B2 (OSRAM)
EP (3) EP2202242A1 (OSRAM)
JP (2) JP3987114B2 (OSRAM)
AT (2) ATE502958T1 (OSRAM)
AU (1) AU3202797A (OSRAM)
CA (1) CA2252896C (OSRAM)
DE (2) DE69735421T2 (OSRAM)
DK (1) DK1754718T3 (OSRAM)
PT (1) PT1754718E (OSRAM)
WO (1) WO1997040145A1 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2221567A1 (en) * 1995-06-12 1996-12-27 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Ned Erlandse Rode Kruis Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
ATE502958T1 (de) 1996-04-24 2011-04-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
EP1351986A2 (en) * 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1831242B1 (en) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
WO2006108590A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
CA2816575C (en) * 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
ES2600081T3 (es) 2011-10-18 2017-02-07 Csl Behring Gmbh Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
DK2768521T3 (en) 2011-10-18 2016-10-24 Csl Behring Gmbh Combined use of a sulfated glykosamin glycan and a Hyaluronidase to improve bio-availability of factor VIII
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
WO2014041500A2 (en) * 2012-09-12 2014-03-20 Centre For Bioseparation Technology-Vit Double mutant coagulation factor viii and methods thereof
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
HK1215174A1 (zh) 2012-11-29 2016-08-19 Bayer Healthcare Llc 針對活化蛋白c的人源化單克隆抗體及其用途
ES2680942T3 (es) * 2013-03-15 2018-09-11 Bayer Healthcare Llc Variante de polipéptidos del factor VIII y procedimientos para su producción y utilización
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
JP6704420B2 (ja) * 2015-03-06 2020-06-03 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト フォンヴィレブランド因子の半減期を改善するための化合物
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
KR20180012303A (ko) 2015-05-22 2018-02-05 체에스엘 베링 리컴비넌트 퍼실리티 아게 변형된 폰 빌레브란트 인자의 제조 방법
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220403005A1 (en) * 2019-12-06 2022-12-22 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
JP2865861B2 (ja) 1989-11-17 1999-03-08 ノボ ノルディスク アクティーゼルスカブ 第▲ｖｉｉｉ▼：ｃ因子活性を有するタンパク質複合体およびその製法
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
ATE502958T1 (de) 1996-04-24 2011-04-15 Univ Michigan Gegen inaktivierung resistenter faktor viii

Also Published As

Publication number Publication date
EP1754718A3 (en) 2007-05-16
EP1754718A2 (en) 2007-02-21
AU3202797A (en) 1997-11-12
DE69735421T2 (de) 2006-10-19
EP0910628A4 (en) 2001-05-02
US6838437B2 (en) 2005-01-04
DE69735421D1 (de) 2006-05-04
US20060014683A1 (en) 2006-01-19
EP0910628A1 (en) 1999-04-28
CA2252896A1 (en) 1997-10-30
JP4250661B2 (ja) 2009-04-08
JP2000511407A (ja) 2000-09-05
DK1754718T3 (da) 2011-07-18
ATE319817T1 (de) 2006-03-15
PT1754718E (pt) 2011-07-13
DE69740154D1 (de) 2011-05-05
CA2252896C (en) 2009-03-10
JP2007228973A (ja) 2007-09-13
WO1997040145A1 (en) 1997-10-30
US7459534B2 (en) 2008-12-02
EP1754718B1 (en) 2011-03-23
US20020132306A1 (en) 2002-09-19
EP0910628B1 (en) 2006-03-08
EP2202242A1 (en) 2010-06-30
JP3987114B2 (ja) 2007-10-03

Similar Documents

Publication Publication Date Title
ATE319817T1 (de) Gegen inaktivierung resistenter faktor viii
DK0672138T3 (da) Kimære prokoagulante proteiner
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
ATE423194T1 (de) Von-willebrand-faktor (vwf) spaltendes protease- polypeptid, für das polypeptid codierende nukleinsäure und verwendung des polypeptids
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
AU3793493A (en) Therapeutic domains of von willebrand factor
ATE148992T1 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
MX9708426A (es) Polipeptido hk2 de variante estable.
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
MX9806041A (es) Proteina purificada sr-p70.
SE9602822D0 (sv) New receptor
EP1502921A1 (en) Recombinant mutated human factor VIII (FVIII) with improved stability
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
FI921356A0 (fi) Somatostatinreceptor.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1754718

Country of ref document: EP